Cupertino, United States
Novlead Biotech, founded in 2018 and headquartered in the United States, is an emerging player in the Biotechnology, Health Care, and Pharmaceutical industries. The company operates under the slogan, "Say Yes to NO," and specializes in advancing the application of NO (nitric oxide) therapy to combat cardiopulmonary disease and infections.
Novlead Biotech's innovative approach, characterized by their motto "From 0 to N, From Nobel to Noble," underscores their dedication to pushing the boundaries of medical therapies using Nobel Prize-winning research. The company's direction has already garnered significant attention, demonstrated by its successful Series B investment on 24 June 2023. Key investors such as Lilly Asia Ventures, 3E Bioventures Capital, JYTH, and 北京基石创业投资管理中心（有限合伙） show strong confidence in its potential.
